Detalhe da pesquisa
1.
Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
PLoS One
; 17(10): e0274943, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36256646
2.
Active pharmacovigilance of the seasonal trivalent influenza vaccine produced by Instituto Butantan: A prospective cohort study of five target groups.
PLoS One
; 16(2): e0246540, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33571237
3.
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
Lancet Infect Dis
; 20(7): 839-850, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220283
4.
Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan.
Rev Inst Med Trop Sao Paulo
; 60: e37, 2018 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30066805
5.
Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.
Vaccine
; 33(50): 7121-5, 2015 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26458796
6.
A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
Vaccine
; 29(48): 8974-81, 2011 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-21945258